Lixisenatide Glycemic Control in Pediatric Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes mellitus in pediatric patients, particularly those with high body mass index (BMI) ≥ 30 kg/m², often fail to adequately control blood glucose levels, leading to increased risks of cardiovascular diseases and diabetes complications due to insufficient glycemic control, especially when metformin monotherapy or basal insulin therapy is insufficient.
Innovation Solution
The use of lixisenatide, a GLP-1 analogue, either alone or in combination with metformin and/or basal insulin, to improve glycemic control in pediatric patients with type 2 diabetes mellitus, as it reduces postprandial plasma glucose, insulin, and glucagon secretion, thereby achieving better glucose regulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metformin monotherapy or basal insulin therapy is used in pediatric patients with high BMI, then treatment simplicity is maintained, but glycemic control becomes insufficient
Solution Approach 1:
The patent combines lixisenatide with metformin and/or basal insulin to create a multi-component therapeutic regimen. This merging of treatments addresses the insufficiency of monotherapy while managing the complexity through structured combination protocols for pediatric patients with high BMI and inadequate glycemic control
2Reliability
If conventional treatments are used in pediatric patients with type 2 diabetes, then treatment accessibility is maintained, but diabetes complications increase due to insufficient glycemic control
Solution Approach 1:
The patent applies preliminary anti-action by using lixisenatide to proactively reduce postprandial glucose excursions and suppress glucagon secretion before hyperglycemia can lead to complications. This preventive approach targets the underlying mechanisms of glucose dysregulation in pediatric type 2 diabetes to prevent future complications
3Reliability
If lixisenatide is added to improve glycemic control, then glycemic control improves, but treatment complexity increases
Solution Approach 1:
The patent implements a dynamic treatment approach where lixisenatide is added based on specific clinical criteria (BMI ≥30 kg/m² and inadequate control on metformin and/or basal insulin). The treatment regimen can be adjusted by modifying lixisenatide dosage or discontinuing based on glycemic control response, allowing flexibility to balance efficacy with treatment complexity
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention refers to lixisenatide for use in pediatrics.